Molecular monitoring during dose reduction predicts recurrence after TKI cessation in CML

被引：17
作者：
Gottschalk, Andrea [1 ]
Glauche, Ingmar [1 ]
Cicconi, Silvia [2 ]
Clark, Richard E. [3 ]
Roeder, Ingo [1 ,4 ]
机构：
[1] Tech Univ Dresden, Carl Gustav Carus Fac Med, Inst Med Informat & Biometry, Fetscherstr 74, D-01307 Dresden, Germany
[2] Univ Liverpool, Dept Mol & Clin Canc Med, Liverpool, Merseyside, England
[3] Univ Liverpool, Inst Translat Med, Liverpool, Merseyside, England
[4] Natl Ctr Tumor Dis, Partner Site Dresden, Dresden, Germany
来源：
BLOOD | 2020年 / 135卷 / 10期
关键词：
CHRONIC MYELOID-LEUKEMIA; IMATINIB;
D O I：
10.1182/blood.2019003395
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：766 / 769
页数：4
相关论文
共 11 条
[1]   Chronic myeloid leukaemia [J].
Apperley, Jane F. .
LANCET, 2015, 385 (9976) :1447-1459
[2]   Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population [J].
Bower, Hannah ;
Bjorkholm, Magnus ;
Dickman, Paul W. ;
Hoglund, Martin ;
Lambert, Paul C. ;
Andersson, Therese M. -L. .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (24) :2851-+
[3]   Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response [J].
Cervantes, Francisco ;
Correa, Juan-Gonzalo ;
Perez, Isabel ;
Garcia-Gutierrez, Valentin ;
Redondo, Sara ;
Colomer, Dolors ;
Jimenez-Velasco, Antonio ;
Steegmann, Juan-Luis ;
Sanchez-Guijo, Fermin ;
Ferrer-Marin, Francisca ;
Pereira, Arturo ;
Osorio, Santiago .
ANNALS OF HEMATOLOGY, 2017, 96 (01) :81-85
[4]   De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial [J].
Clark, Richard E. ;
Polydoros, Fotios ;
Apperley, Jane F. ;
Milojkovic, Dragana ;
Rothwell, Katherine ;
Pocock, Christopher ;
Byrne, Jennifer ;
de lavallade, Hugues ;
Osborne, Wendy ;
Robinson, Lisa ;
O'Brien, Stephen G. ;
Read, Lucy ;
Foroni, Letizia ;
Copland, Mhairi .
LANCET HAEMATOLOGY, 2019, 6 (07) :E375-E383
[5]   De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial [J].
Clark, Richard E. ;
Polydoros, Fotios ;
Apperley, Jane F. ;
Milojkovic, Dragana ;
Pocock, Christopher ;
Smith, Graeme ;
Byrne, Jenny L. ;
de lavallade, Hugues ;
O'Brien, Stephen G. ;
Coffey, Tony ;
Foroni, Letizia ;
Copland, Mhairi .
LANCET HAEMATOLOGY, 2017, 4 (07) :E310-E316
[6]   Treatment-free remission with first- and second-generation tyrosine kinase inhibitors [J].
Cortes, Jorge ;
Rea, Delphine ;
Lipton, Jeffrey H. .
AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (03) :346-357
[7]   Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data [J].
Fassoni, Artur C. ;
Baldow, Christoph ;
Roeder, Ingo ;
Glauche, Ingmar .
HAEMATOLOGICA, 2018, 103 (11) :1825-1834
[8]   Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring [J].
Jabbour, Elias ;
Kantarjian, Hagop .
AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (02) :253-265
[9]   Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia [J].
Pfirrmann, M. ;
Baccarani, M. ;
Saussele, S. ;
Guilhot, J. ;
Cervantes, F. ;
Ossenkoppele, G. ;
Hoffmann, V. S. ;
Castagnetti, F. ;
Hasford, J. ;
Hehlmann, R. ;
Simonsson, B. .
LEUKEMIA, 2016, 30 (01) :48-56
[10]   Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease [J].
Rousselot, Philippe ;
Charbonnier, Aude ;
Cony-Makhoul, Pascale ;
Agape, Philippe ;
Nicolini, Franck E. ;
Varet, Bruno ;
Gardembas, Martine ;
Etienne, Gabriel ;
Rea, Delphine ;
Roy, Lydia ;
Escoffre-Barbe, Martine ;
Guerci-Bresler, Agnes ;
Tulliez, Michel ;
Prost, Stephane ;
Spentchian, Marc ;
Cayuela, Jean Michel ;
Reiffers, Josy ;
Chomel, Jean Claude ;
Turhan, Ali ;
Guilhot, Joelle ;
Guilhot, Francois ;
Mahon, Francois-Xavier .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (05) :424-U59
12